Table 2.
Significant associations between the tested polymorphisms and analysed phenotypes
| Gene | SNP | Phenotypes | Model of inheritance or MAFa | OR (95% CI) | P-value | Sample power (%) | BADGE class for genetic association |
|---|---|---|---|---|---|---|---|
| RXRA | rs749759 | MI vs without MI | Recessive | 2.22 (1.28–3.84) | 0.004 | 75.6 | Fifth |
| RXRA | rs10776909 | MI vs without MI | Recessive | 3.08 (1.60–5.93) | 0.0004 | 85.1 | Fourth |
| Additive | 3.17 (1.63–6.18) | 0.0004 | 99.9 | Fourth | |||
| ENHO | rs2281997 | Dyslipidaemia vs non-dyslipidaemia by K/DOQI criteria |
Recessive | 2.87 (1.65–4.99) | 0.0001 | 99.9 | Third/Fourth |
| Additive | 3.16 (1.80–5.57) | 0.00003 | 99.9 | Third | |||
| MAF (T vs. C allele) | 1.49 (1.21–1.84) | 0.0002 | Fourth | ||||
| ENHO | rs2281997 | Hyper-LDL cholesterolaemic dyslipidaemia vs non-dyslipidaemia by K/DOQI criteria |
Dominant | 1.55 (1.14–2.11) | 0.006 | 78.3 | Fifth |
| Recessive | 3.10 (1.71–5.63) | 0.0001 | 86.5 | Third/Fourth | |||
| Additive | 3.53 (1.91–6.53) | 0.00003 | 99.9 | Third | |||
| MAF (T vs. C allele) | 1.59 (1.25–2.02) | 0.0002 | Fourth | ||||
| ENHO | rs2281997 | LDL cholesterol ≥100 mg/dL vs LDL cholesterol < 100 |
Dominant | 1.43 (1.10–1.87) | 0.009 | 74.3 | Fifth |
| Recessive | 2.18 (1.32–3.60) | 0.002 | 75.0 | Fifth/Fourth | |||
| Additive | 2.44 (1.45–4.10) | 0.0006 | 99.9 | Fourth | |||
| MAF (T vs. C allele) | 1.43 (1.16–1.76) | 0.0007 | Fourth | ||||
| ENHO | rs2281997 | Atherogenic dyslipidaemia vs without atherogenic dyslipidaemia |
dominant | 0.65 (0.50–0.85) | 0.002 | 88.7 | Fifth/Fourth |
| additive | 0.49 (0.29–0.81) | 0.005 | 99.9 | Fifth | |||
| MAF (T vs. C allele) | 0.70 (0.57–0.86) | 0.0007 | Fourth |
Abbreviations: MAF minor allele frequency, MI myocardial infarction
a MAF is referred to the frequency of the respective major allele. The minor allele is underlined
Detailed analyses for all tested associations are shown in the Additional file 1